Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IPHA 
Innate Pharma (IPHA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: IPHA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.86
1 Year Target Price $7.86
| 1 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -67.58% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 171.87M USD | Price to earnings Ratio - | 1Y Target Price 7.86 |
Price to earnings Ratio - | 1Y Target Price 7.86 | ||
Volume (30-day avg) 3 | Beta 0.98 | 52 Weeks Range 1.29 - 3.51 | Updated Date 07/11/2025 |
52 Weeks Range 1.29 - 3.51 | Updated Date 07/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.72 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -245.87% | Operating Margin (TTM) -324.87% |
Management Effectiveness
Return on Assets (TTM) -22.52% | Return on Equity (TTM) -162.91% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 107173655 | Price to Sales(TTM) 8.54 |
Enterprise Value 107173655 | Price to Sales(TTM) 8.54 | ||
Enterprise Value to Revenue 7.24 | Enterprise Value to EBITDA -6.94 | Shares Outstanding 92164896 | Shares Floating 59214654 |
Shares Outstanding 92164896 | Shares Floating 59214654 | ||
Percent Insiders - | Percent Institutions 0.24 |
Upturn AI SWOT
Innate Pharma
Company Overview
History and Background
Innate Pharma S.A. is a French biopharmaceutical company dedicated to improving treatment through innovative therapeutic antibodies that exploit the innate immune system. Founded in 1999, it has grown through research partnerships and clinical development.
Core Business Areas
- Research and Development: Focused on discovering and developing first-in-class immunotherapies for cancer and inflammatory diseases. Targets include NK cell receptors and other immune checkpoints.
- Licensing and Partnerships: Generating revenue through licensing agreements and strategic collaborations with pharmaceutical companies to develop and commercialize Innate Pharma's assets.
Leadership and Structure
The company is led by a management team with expertise in immunotherapy and drug development. Its organizational structure includes research, clinical development, and commercial functions.
Top Products and Market Share
Key Offerings
- Monalizumab: A checkpoint inhibitor targeting NKG2A, co-developed with AstraZeneca. Aims to restore anti-cancer immunity by blocking the NKG2A receptor on tumor-infiltrating lymphocytes and NK cells. Clinical trials are ongoing in various cancers. Market share is currently pre-commercialization. Competitors include PD-1/PD-L1 inhibitors from Merck (MRK), Bristol Myers Squibb (BMY), and Roche (RHHBY).
- Lacutamab: Anti-KIR3DL2 antibody in clinical trials for cutaneous T-cell lymphoma. Currently pre-commercialization. Competitors include other therapies for CTCL, such as Mogamulizumab (Poteligeo) from Kyowa Kirin.
Market Dynamics
Industry Overview
The immunotherapy market is experiencing significant growth, driven by advances in understanding the immune system's role in cancer and other diseases. It is dominated by checkpoint inhibitors, cell therapies, and other novel approaches.
Positioning
Innate Pharma focuses on innate immunity, a less-explored area compared to adaptive immunity. This potentially gives them a competitive advantage through differentiated targets and mechanisms of action.
Total Addressable Market (TAM)
The global immunotherapy market is projected to reach hundreds of billions of dollars in the coming years. Innate Pharma is positioned to capture a portion of this market through its innovative pipeline, focusing on areas of unmet need such as NK cell-based therapies.
Upturn SWOT Analysis
Strengths
- Innovative pipeline targeting innate immunity
- Strategic partnerships with major pharmaceutical companies (AstraZeneca)
- Strong expertise in antibody engineering and immunology
- Focus on novel targets (NKG2A, KIR3DL2)
Weaknesses
- Reliance on partnerships for commercialization
- High R&D expenses
- Clinical trial risks and uncertainties
- Relatively small company size compared to major players
Opportunities
- Expansion of existing partnerships
- Potential for breakthrough therapies in underserved markets
- Acquisition or merger by a larger pharmaceutical company
- Positive clinical trial results
Threats
- Competition from established immunotherapy companies
- Failure of clinical trials
- Regulatory hurdles and delays
- Pricing pressures on new therapies
Competitors and Market Share
Key Competitors
- MRK
- BMY
- RHHBY
- KYKOF
Competitive Landscape
Innate Pharma differentiates itself through its focus on innate immunity, but it faces competition from larger companies with more resources and established products. Its partnerships are critical for its competitive positioning.
Growth Trajectory and Initiatives
Historical Growth: Innate Pharma's growth has been driven by its research and development pipeline, partnerships, and milestones achieved in clinical trials.
Future Projections: Future growth depends on the success of ongoing clinical trials and the commercial potential of its pipeline assets. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing clinical trials for Monalizumab and Lacutamab, and expanding research collaborations to discover new targets.
Summary
Innate Pharma is a promising biopharmaceutical company focusing on novel immunotherapy approaches. Its strength lies in its innovative pipeline and strategic partnerships. However, it faces risks associated with clinical trial outcomes, competition, and reliance on partners. Positive clinical data and successful commercialization will be crucial for its future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Innate Pharma
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-10-17 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 181 | Website https://www.innate-pharma.com |
Full time employees 181 | Website https://www.innate-pharma.com | ||
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.